A Multi-Center Open-Label Evaluation of the Safety of Sarecycline Tablets in the Treatment of Acne Vulgaris
Phase of Trial: Phase III
Latest Information Update: 11 May 2018
At a glance
- Drugs Sarecycline (Primary)
- Indications Acne vulgaris
- Focus Adverse reactions; Registrational
- Sponsors Actavis
- 23 Feb 2017 Status changed from active, no longer recruiting to completed.
- 30 Aug 2016 Planned End Date changed from 1 Nov 2016 to 1 Sep 2016.
- 01 Dec 2015 Planned number of patients changed from 500 to 490 as reported by ClinicalTrials.gov record.